Rexahn Pharmaceuticals, Inc. (REXN)

[jugygales]

They submitted an IND not a NDA.

The pancreatic cancer data should come out some time this quarter.

http://www.rexahn.com/cms/index.php/2012/01/rexahn-pharmaceuticals-provides-key-goals-for-2012/

• Complete clinical trial of Archexin to treat pancreatic cancer. Rexahn expects to report the results of its Phase II clinical trial of Archexin in pancreatic cancer in the third quarter of 2012. Archexin is a first in class, potent Akt protein kinase inhibitor with the potential to inhibit cancer cell survival and proliferation, angiogenesis, and drug resistance. Archexin has FDA Orphan drug designation for five different cancer types, including renal cell carcinoma, glioblastoma, pancreatic, stomach, and ovarian cancers.